The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy

Antonio Greco; Davide Capodanno; Dominick J. Angiolillo

doi:10.1055/s-0038-1676612

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2019; 119(01): 009-013
DOI: 10.1055/s-0038-1676612

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy

Authors

Antonio Greco

¹Division of Cardiology, CAST, P.O. “Rodolico,” Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele,” University of Catania, Catania, Italy
Davide Capodanno

¹Division of Cardiology, CAST, P.O. “Rodolico,” Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele,” University of Catania, Catania, Italy
Dominick J. Angiolillo

²Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

Abstract

Volltext

Referenzen

References
1 Capodanno D, Alfonso F, Levine GN. , et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy. J Am Coll Cardiol 2018; 72 (23PA) 2915-2931
2 Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 2017; 117 (07) 1240-1248
3 Capodanno D, Greco A. Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple. Thromb Haemost 2018; 118 (06) 949-952
4 Garay A, Ariza-Solé A, Formiga F. , et al. Prediction of post discharge bleeding in elderly patients with acute coronary syndromes: insights from the BleeMACS registry. Thromb Haemost 2018; 118 (05) 929-938
5 Biancari F, Brascia D, Onorati F. , et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost 2017; 117 (03) 445-456
6 Capodanno D, Mehran R, Valgimigli M. , et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 2018; 15 (08) 480-496
7 Angiolillo DJ, Rollini F, Storey RF. , et al. International expert consensus on switching platelet P2Y₁₂ receptor-inhibiting therapies. Circulation 2017; 136 (20) 1955-1975
8 Moon JY, Franchi F, Rollini F, Angiolillo DJ. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis 2018; 60 (4-5): 478-490
9 Serebruany VL, Kim MH, Cabrera-Fuentes HA. , et al. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Thromb Haemost 2017; 117 (05) 934-939
10 Mauri L, Kereiakes DJ, Yeh RW. , et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
11 Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. Lancet 2017; 389 (10073): 987-989
12 Capodanno D, Angiolillo DJDJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost 2010; 104 (03) 471-484
13 Jeong Y-H. “East Asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep 2014; 16 (05) 485
14 Han Y, Xu B, Xu K. , et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv 2016; 9 (02) e003145
15 Hong S-J, Shin D-H, Kim J-S. , et al; IVUS-XPL Investigators. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL Randomized Clinical Trial. JACC Cardiovasc Interv 2016; 9 (14) 1438-1446
16 Gwon H-C, Hahn J-Y, Park KW. , et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125 (03) 505-513
17 Kim B-K, Hong M-K, Shin D-H. , et al; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60 (15) 1340-1348
18 Helft G, Steg PG, Le Feuvre C. , et al; OPTImal DUAL Antiplatelet Therapy Trial Investigators. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 2016; 37 (04) 365-374
19 Collet J-P, Silvain J, Barthélémy O. , et al; ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014; 384 (9954): 1577-1585
20 Valgimigli M, Campo G, Monti M. , et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16) 2015-2026
21 Gilard M, Barragan P, Noryani AAL. , et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015; 65 (08) 777-786
22 Kang J, Park KW, Palmerini T. , et al. Racial differences in ischemia/bleeding risk tradeoff during antiplatelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119 (01) 149-162
23 Levine GN, Jeong Y-H, Goto S. , et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11 (10) 597-606
24 Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiovasc Revasc Med 2018; 19 (06) 689-694
25 Kang J, Kim H-S. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and “Asian Paradox”. Korean Circ J 2018; 48 (07) 537-551
26 Park KW, Jeon K-H, Kang S-H. , et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011; 108 (11) 1556-1563
27 Jin H-Y, Yang T-H, Kim D-I. , et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol 2013; 167 (05) 1877-1881
28 Zhang H-Z, Kim MH, Jeong Y-H. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 2014; 25 (04) 292-299
29 Saito S, Isshiki T, Kimura T. , et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78 (07) 1684-1692
30 Kang H-J, Clare RM, Gao R. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 2015; 169 (06) 899-905.e1
31 Giordana F, Montefusco A, D'Ascenzo F. , et al. Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. Int J Cardiol 2016; 220: 488-495
32 Kang J, Han J-K, Ahn Y. , et al; investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study. Thromb Haemost 2018; 118 (03) 591-600
33 Lutsey PL, Cushman M, Steffen LM. , et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006; 4 (12) 2629-2635
34 Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A. ; JACC Study Group. C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis 2009; 207 (01) 291-297
35 Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost 2011; 9 (10) 1877-1882
36 Faber DR, de Groot PG, Visseren FLJ. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10 (05) 554-563
37 Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin North Am 2009; 38 (02) 363-379